Pharmacokinetics of Nebulized Amikacin in Patients With Pneumonia Undergoing Mechanical Ventilation

• Status: Unknown status
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Inclusion of patients undergoing mechanical ventilation and presenting a pneumonia in order to determine serum pharmacokinetics of nebulized amikacin. The primary aim is to determine the dose of amikacin to be nebulized in order to observe amikacin serum concentrations close to but inferior to those observed after standart intravenous amikacin infusion.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Association Pour La Promotion A Tours De La Reanimation Medicale
• Treatments: Amikacin

Criteria

Inclusion Criteria:

• Patients admitted to intensive care unit.

• Patients undergoing mechanical ventilation for more than 48H.

• Suspicion of ventilator associated pneumonia.

Exclusion Criteria:

• Allergy to amikacin or any compound of the medication.

• Body mass index > 30 kg/m2.

• Myasthenia gravis.

• Acute or chronic renal failure.

• Vestibulo-cochlear disease.

• Pregnancy.

• Brain death.